Found: 80
Select item for more details and to access through your institution.
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221090221
- By:
- Publication type:
- Article
Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 6, p. 1449, doi. 10.1007/s10637-010-9438-y
- By:
- Publication type:
- Article
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 4, p. 389, doi. 10.1159/000535338
- By:
- Publication type:
- Article
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 1, p. 44, doi. 10.1159/000525499
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 296, doi. 10.1159/000513486
- By:
- Publication type:
- Article
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China.
- Published in:
- Cost Effectiveness & Resource Allocation, 2018, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12962-018-0112-0
- By:
- Publication type:
- Article
A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma.
- Published in:
- Molecular Therapy, 2013, v. 21, n. 7, p. 1456, doi. 10.1038/mt.2013.79
- By:
- Publication type:
- Article
Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment.
- Published in:
- Oncology & Therapy, 2018, v. 6, n. 1, p. 21, doi. 10.1007/s40487-017-0055-1
- By:
- Publication type:
- Article
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00664
- By:
- Publication type:
- Article
Issue Cover.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. i, doi. 10.1111/liv.14277
- By:
- Publication type:
- Article
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma.
- Published in:
- Liver International, 2019, v. 39, n. 12, p. 2214, doi. 10.1111/liv.14223
- By:
- Publication type:
- Article
Current progress and advances in hepatocellular carcinoma: highlights from the 2022 ESMO annual meeting.
- Published in:
- Journal of Practical Oncology, 2023, v. 38, n. 1, p. 5, doi. 10.13267/j.cnki.syzlzz.2023.002
- By:
- Publication type:
- Article
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
- Published in:
- Drug Design, Development & Therapy, 2021, v. 15, p. 1873, doi. 10.2147/DDDT.S304857
- By:
- Publication type:
- Article
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211039928
- By:
- Publication type:
- Article
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.
- Published in:
- British Journal of Cancer, 2022, v. 127, n. 12, p. 2241, doi. 10.1038/s41416-022-02001-3
- By:
- Publication type:
- Article
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 5, p. 1046, doi. 10.1007/s10120-024-01516-3
- By:
- Publication type:
- Article
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 558, doi. 10.1007/s10120-024-01466-w
- By:
- Publication type:
- Article
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 1, p. 234, doi. 10.1007/s10120-015-0457-4
- By:
- Publication type:
- Article
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
- Published in:
- Gastric Cancer, 2015, v. 18, n. 1, p. 168, doi. 10.1007/s10120-014-0351-5
- By:
- Publication type:
- Article
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer.
- Published in:
- Oncology Letters, 2019, v. 17, n. 5, p. 4701
- By:
- Publication type:
- Article
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
- Published in:
- BioDrugs, 2021, v. 35, n. 4, p. 445, doi. 10.1007/s40259-021-00484-9
- By:
- Publication type:
- Article
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02841-7
- By:
- Publication type:
- Article
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
- Published in:
- Acta Biochimica et Biophysica Sinica, 2009, v. 41, n. 5, p. 429, doi. 10.1093/abbs/gmp027
- By:
- Publication type:
- Article
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non–Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
- Published in:
- Oncologist, 2022, v. 27, n. 12, p. e938, doi. 10.1093/oncolo/oyac183
- By:
- Publication type:
- Article
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. e1567, doi. 10.1002/onco.13826
- By:
- Publication type:
- Article
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. e702, doi. 10.1634/theoncologist.2018-0839
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
- Published in:
- Oncologist, 2019, v. 24, p. S3, doi. 10.1634/theoncologist.2019-IO-S1-s01
- By:
- Publication type:
- Article
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study.
- Published in:
- Oncologist, 2014, v. 19, n. 11, p. 1168, doi. 10.1634/theoncologist.2014-0190
- By:
- Publication type:
- Article
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 9, p. 4570, doi. 10.1002/cam4.1664
- By:
- Publication type:
- Article
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using realworld data in third-line treatment of metastatic colorectal cancer.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1044328
- By:
- Publication type:
- Article
Inhibitory Effect of Endostar on Specific Angiogenesis Induced by Human Hepatocellular Carcinoma.
- Published in:
- Gastroenterology Research & Practice, 2015, v. 2015, p. 1, doi. 10.1155/2015/957574
- By:
- Publication type:
- Article
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 24, p. 4585, doi. 10.1002/cncr.33870
- By:
- Publication type:
- Article
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
- Published in:
- Journal of Gastroenterology & Hepatology, 2020, v. 35, n. 8, p. 1307, doi. 10.1111/jgh.14974
- By:
- Publication type:
- Article
Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version).
- Published in:
- Chinese Journal of Lung Cancer, 2020, v. 23, n. 2, p. 65, doi. 10.3779/j.issn.1009-3419.2020.02.01
- By:
- Publication type:
- Article
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211039928
- By:
- Publication type:
- Article
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919889001
- By:
- Publication type:
- Article
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01095-1
- By:
- Publication type:
- Article
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00886-2
- By:
- Publication type:
- Article
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 17, p. 2694, doi. 10.1002/cncr.28766
- By:
- Publication type:
- Article
Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma†.
- Published in:
- Japanese Journal of Clinical Oncology, 2012, v. 42, n. 9, p. 836, doi. 10.1093/jjco/hys110
- By:
- Publication type:
- Article
Prognostic factors for patients with advanced non-small cell lung cancer treated with gemcitabine-platinum as first-line therapy in an observational setting in China.
- Published in:
- Thoracic Cancer, 2014, v. 5, n. 4, p. 319, doi. 10.1111/1759-7714.12095
- By:
- Publication type:
- Article
Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
- Published in:
- BMC Cancer, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2407-13-136
- By:
- Publication type:
- Article
Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
- Published in:
- 2013
- By:
- Publication type:
- journal article